
Denis Larsimont

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8211346/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Abstract P1-02-09: Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC). Cancer Research, 2022, 82, P1-02-09-P1-02-09.	0.9	0
2	Abstract P4-02-02: The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer. Cancer Research, 2022, 82, P4-02-02-P4-02-02.	0.9	0
3	Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. British Journal of Cancer, 2022, 127, 988-1013.	6.4	30
4	Transcriptional output, cell-type densities, and normalization in spatial transcriptomics. Journal of Molecular Cell Biology, 2021, 12, 906-908.	3.3	27
5	Inferior epigastric artery lymph nodes: A pathway for systemic dissemination from peritoneal carcinomatosis?. Journal of Surgical Oncology, 2021, 123, 311-314.	1.7	4
6	Absence of residual fluorescence in the surgical bed at near-infrared fluorescence imaging predicts negative margins at final pathology in patients treated with breast-conserving surgery for breast cancer. European Journal of Surgical Oncology, 2021, 47, 269-275.	1.0	19
7	Clinicoâ€metabolic characterization improves the prognostic value of histological growth patterns in patients undergoing surgery for colorectal liver metastases. Journal of Surgical Oncology, 2021, 123, 1773-1783.	1.7	7
8	The genomic landscape of carcinomas with mucinous differentiation. Scientific Reports, 2021, 11, 9478.	3.3	9
9	Circulating Tumor DNA to Interrogate the Safety of Letrozole-Associated Controlled Ovarian Stimulation for Fertility Preservation in Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 686625.	2.8	5
10	Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment. Frontiers in Molecular Biosciences, 2021, 8, 673042.	3.5	19
11	Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity. Journal of Clinical Investigation, 2021, 131, .	8.2	70
12	Extended time interval between diagnosis and surgery does not improve the outcome in patients operated for resection or ablation of breast cancer liver metastases. European Journal of Surgical Oncology, 2020, 46, 229-234.	1.0	5
13	Infiltrative tumour growth pattern correlates with poor outcome in oesophageal cancer. BMJ Open Gastroenterology, 2020, 7, e000431.	2.7	2
14	Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome. EBioMedicine, 2020, 56, 102793.	6.1	22
15	Digital analysis of distant and cancer-associated mammary adipocytes. Breast, 2020, 54, 179-186.	2.2	5
16	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. Clinical Cancer Research, 2020, 26, 6254-6265.	7.0	22
17	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. Nature Communications, 2020, 11, 6335.	12.8	46
18	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	5.2	106

DENIS LARSIMONT

#	Article	IF	CITATIONS
19	The path to a better biomarker: application of a risk management framework for the implementation of PD‣1 and TILs as immunoâ€oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	4.5	142
20	Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients. Npj Breast Cancer, 2020, 6, 64.	5.2	20
21	Systemic Sentinel Lymph Node Detection Using Fluorescence Imaging After Indocyanine Green Intravenous Injection in Colorectal Cancer: Protocol for a Feasibility Study. JMIR Research Protocols, 2020, 9, e17976.	1.0	8
22	Reprogramming of Energy Metabolism: Increased Expression and Roles of Pyruvate Carboxylase in Papillary Thyroid Cancer. Thyroid, 2019, 29, 845-857.	4.5	25
23	Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. British Journal of Cancer, 2019, 120, 913-921.	6.4	11
24	Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer. Journal of the National Cancer Institute, 2019, 111, 742-746.	6.3	40
25	BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. Cancer Letters, 2019, 450, 88-97.	7.2	33
26	ESR1 mutations in metastatic lobular breast cancer patients. Npj Breast Cancer, 2019, 5, 9.	5.2	26
27	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. Breast Cancer Research, 2019, 21, 151.	5.0	30
28	FOXP1 negatively regulates tumor infiltrating lymphocyte migration in human breast cancer. EBioMedicine, 2019, 39, 226-238.	6.1	36
29	Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer. JCI Insight, 2019, 4, .	5.0	182
30	Histological growth pattern as a potential prognostic factor in patients operated for breast cancer liver metastases Journal of Clinical Oncology, 2019, 37, e12576-e12576.	1.6	1
31	Histological growth pattern as a potential marker of oligometastatic disease in patients operated for colorectal liver metastases Journal of Clinical Oncology, 2019, 37, e15093-e15093.	1.6	0
32	Immune Infiltration in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 768-776.	6.3	76
33	<scp>G</scp> enomic hotspots but few recurrent fusion genes in breast cancer. Genes Chromosomes and Cancer, 2018, 57, 331-338.	2.8	18
34	Distinctive Desmoplastic 3D Morphology Associated With BRAFV600E in Papillary Thyroid Cancers. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1102-1111.	3.6	11
35	ICCâ€fluorescence imaging for detection of peritoneal metastases and residual tumoral scars in locally advanced ovarian cancer: A pilot study. Journal of Surgical Oncology, 2018, 117, 228-235.	1.7	42
36	Antigen Specificity and Clinical Significance of IgG and IgA Autoantibodies Produced in situ by Tumor-Infiltrating B Cells in Breast Cancer. Frontiers in Immunology, 2018, 9, 2660.	4.8	65

DENIS LARSIMONT

#	Article	IF	CITATIONS
37	Ex vivo indocyanine green fluorescence imaging for the detection of lymph node involvement in advancedâ€stage ovarian cancer. Journal of Surgical Oncology, 2018, 118, 1163-1169.	1.7	11
38	ICG fluorescence imaging as a new tool for optimization of pathological evaluation in breast cancer tumors after neoadjuvant chemotherapy. PLoS ONE, 2018, 13, e0197857.	2.5	23
39	The impact of breast MRI workup on tumor size assessment and surgical planning in patients with early breast cancer. Breast Journal, 2018, 24, 927-933.	1.0	17
40	Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nature Communications, 2017, 8, 14944.	12.8	126
41	Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. Modern Pathology, 2017, 30, 1204-1212.	5.5	81
42	<scp>CDK</scp> 4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib. EMBO Molecular Medicine, 2017, 9, 1052-1066.	6.9	65
43	Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. Oncolmmunology, 2017, 6, e1257452.	4.6	169
44	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Frontiers in Immunology, 2017, 8, 1412.	4.8	80
45	N-Acetylcysteine breaks resistance to trastuzumab caused by MUC4 overexpression in human HER2 positive BC-bearing nude mice monitored by 89Zr-Trastuzumab and 18F-FDG PET imaging. Oncotarget, 2017, 8, 56185-56198.	1.8	11
46	Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 2185-2196.	2.5	32
47	Ex vivo detection of tumoral lymph nodes of colorectal origin with fluorescence imaging after intraoperative intravenous injection of indocyanine green. Journal of Surgical Oncology, 2016, 114, 348-353.	1.7	26
48	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. JAMA Oncology, 2016, 2, 217.	7.1	21
49	Feasibility Study of EndoTAC-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer. PLoS ONE, 2016, 11, e0154009.	2.5	27
50	Sentinel Lymph Node Detection by Blue Dye Versus Indocyanine Green Fluorescence Imaging in Colon Cancer. Anticancer Research, 2016, 36, 4853-4858.	1.1	35
51	Uncovering the genomic heterogeneity of multifocal breast cancer. Journal of Pathology, 2015, 236, 457-466.	4.5	72
52	No significant viral transcription detected in whole breast cancer transcriptomes. BMC Cancer, 2015, 15, 147.	2.6	15
53	Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. Cell Reports, 2015, 13, 277-289.	6.4	179
54	Feasibility study of cationic liposome-encapsulated paclitaxel in combination with paclitaxel followed by FEC as induction therapy in HER2-negative breast cancer Journal of Clinical Oncology, 2013, 31, e12008-e12008.	1.6	0

DENIS LARSIMONT

#	Article	IF	CITATIONS
55	Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations Journal of Clinical Oncology, 2013, 31, 11003-11003.	1.6	О
56	HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice. Anticancer Research, 2002, 22, 2485-90.	1.1	8
57	Sensitivity of HER-2/neu Antibodies in Archival Tissue Samples of Invasive Breast Carcinomas. American Journal of Clinical Pathology, 2000, 113, 675-682.	0.7	84
58	Establishment and characterization of three new breast-cancer cell lines. , 1998, 76, 677-683.		19